Table 1.

Viral kinetic and pharmacodynamic parameters and IL28B polymorphism

	All (n = 26 or 21**)		Genotype-1 (n=15)		Genotype-3 (n=11)		P value
Viral response parameter
	CC	TC/TT	CC	TC/TT	CC	TC/TT	All, Gen-1, Gen-3
1st phase viral decline, median [log10(V0/Vmin)] and (IQR)	1.7(0.6)	0.9(0.8)	1.5(0.3*)	0.7(0.9)	1.8(0.6)	1.4(0.1*)	0.005, 0.08, 0.1
ε7max [%], median (IQR)	94(11)	81(45)	91(6*)	76(44)	95(10)	86(14*)	0.008, 0.19, 0.10
ε7average [%], median (IQR)	92(13)	77(45)	87(9*)	73(45)	93(11)	84(13*)	0.008, 0.12, 0.10
εmax [%], median (IQR)	96(6)	87(33)	95(3*)	84(35)	96(9)	91(14*)	0.044, 0.11, 0.6
EC50, median (IQR)	1.3(1.8)	3.3(11.5)	2.9(2.4*)	3.6(11.4)	1.0(1.2)	3.0 (2.3*)	0.02, 0.6, 0.10
Viral rebound [Vd7/Vmin], median (IQR)	1.6 (2.1)	1.7 (2.7)	1.1(0.4)	1.7(4.4)	1.7(1.0*)	2.1(5.7)	0.3, 0.11, 1.0
slower phase slope decline (d7–d15), median [log/wk] and (IQR)	1.13(1.12)	0.40(0.51)	1.13(0.55*)	0.32(0.61)	1.0 (1.3)	1.18 (0. 46*)	0.046, 0.11, 0.7
slower phase slope decline (d2–d29), median [log/wk] and (IQR)	0.67(0.64)	0.26(0.41)	0.54(0.25*)	0.22(0.20)	0.70(0.89)	0.98 (0.37*)	0.01, 0.02, 0.7
δ[1/day], median (IQR)	0.25(0.16)	0.13(0.10)	0.20(0.11*)	0.11(0.05)	0.25(0.13)	0.18(0.13*)	0.11, 0.11, 0.7

^*One standard deviation; IQR, interquartile range; V₀, baseline HCV RNA level; V_min, the observed nadir HCV RNA in each patient¹⁶ during the administration of the first dose of PEG-IFN; V_7d, HCV RNA level at day 7 of therapy; δ, death/loss rate of HCV-infected cells; EC₅₀, PEG-IFN concentration at which the drug’s effectiveness in blocking viral production is half its maximum; ε_7max, maximum PEG-IFN effectiveness during the first week of therapy; ε_7average, average PEG-IFN effectiveness during the first week of therapy; ε_max, maximum PEG-IFN effectiveness from week 4 to week 12 of therapy;

^**n=21 for δ, EC₅₀, ε_7max, ε_7average, ε_max parameters as recently estimated¹⁷.